Analysis of peripheral blood immune cells after prophylactic immunization with HPV-16/18 ASO4-adjuvanted vaccine

Persistent infection with oncogenic types of human papillomavirus (HPV) is a causal factor for more than 99% of cervical cancers. Recently, prophylactic vaccines have been developed to prevent infections with cancer-associated HPV types (HPV16 and HPV18). The aim of this study was to analyze the cha...

Full description

Bibliographic Details
Main Authors: Iwona Hus, Joanna Gonet-Sebastianka, Agata Surdacka, Agnieszka Bojarska-Junak, Jacek Roliński
Format: Article
Language:English
Published: Index Copernicus International S.A. 2015-04-01
Series:Postępy Higieny i Medycyny Doświadczalnej
Subjects:
Online Access:http://phmd.pl/gicid/01.3001.0009.6529
id doaj-13a7fa7160bc4721ab061025a76fe4a6
record_format Article
spelling doaj-13a7fa7160bc4721ab061025a76fe4a62020-11-24T23:15:40ZengIndex Copernicus International S.A.Postępy Higieny i Medycyny Doświadczalnej0032-54491732-26932015-04-016954354810.5604/01.3001.0009.652901.3001.0009.6529Analysis of peripheral blood immune cells after prophylactic immunization with HPV-16/18 ASO4-adjuvanted vaccineIwona Hus0Joanna Gonet-Sebastianka1Agata Surdacka2Agnieszka Bojarska-Junak3Jacek Roliński4Department of Clinical Transplantology, Medical University of Lublin, PolandDepartment of Gynaecology and Obstetrics, Specialist Hospital in Jasło, PolandDepartment of Clinical Immunology and Immunotherapy, Medical University of Lublin, PolandDepartment of Clinical Immunology and Immunotherapy, Medical University of Lublin, PolandDepartment of Clinical Immunology and Immunotherapy, Medical University of Lublin, PolandPersistent infection with oncogenic types of human papillomavirus (HPV) is a causal factor for more than 99% of cervical cancers. Recently, prophylactic vaccines have been developed to prevent infections with cancer-associated HPV types (HPV16 and HPV18). The aim of this study was to analyze the changes in the immune system that occur within four weeks of the first dose of HPV-16/18 ASO4-adjuvanted vaccine. Assessment of the percentages of selected cell populations in peripheral blood of 20 healthy volunteers vaccinated with Cervarix was performed using flow cytometry. The analysis revealed an increase in the proportion of activated B and CD4+ T helper cells and an absence of significant differences in cytotoxic CD8+ T lymphocytes, indicating activation of the humoral response after vaccination, without a significant effect on cellular response. There were no significant changes in the NK cell population, and there was a reduction of the percentage of NKT-like cells, which may result from expiry of the primary response at the time of analysis. The presented results are preliminary, and in the context of the increasing use of the anti-HPV vaccine, it would be worth continuing the study in larger groups of patients and at earlier and later time points in combination with the measurement of specific anti-HPV16 and -HPV18 antibody levels. Such an assessment could therefore contribute not only to better understanding of the exact mechanism of action of the vaccine, but also to defining the immunological parameters that determine its effectiveness. http://phmd.pl/gicid/01.3001.0009.6529cervical cancerhuman papilloma virus (HPV)prophylactic vaccineimmune cell response
collection DOAJ
language English
format Article
sources DOAJ
author Iwona Hus
Joanna Gonet-Sebastianka
Agata Surdacka
Agnieszka Bojarska-Junak
Jacek Roliński
spellingShingle Iwona Hus
Joanna Gonet-Sebastianka
Agata Surdacka
Agnieszka Bojarska-Junak
Jacek Roliński
Analysis of peripheral blood immune cells after prophylactic immunization with HPV-16/18 ASO4-adjuvanted vaccine
Postępy Higieny i Medycyny Doświadczalnej
cervical cancer
human papilloma virus (HPV)
prophylactic vaccine
immune cell response
author_facet Iwona Hus
Joanna Gonet-Sebastianka
Agata Surdacka
Agnieszka Bojarska-Junak
Jacek Roliński
author_sort Iwona Hus
title Analysis of peripheral blood immune cells after prophylactic immunization with HPV-16/18 ASO4-adjuvanted vaccine
title_short Analysis of peripheral blood immune cells after prophylactic immunization with HPV-16/18 ASO4-adjuvanted vaccine
title_full Analysis of peripheral blood immune cells after prophylactic immunization with HPV-16/18 ASO4-adjuvanted vaccine
title_fullStr Analysis of peripheral blood immune cells after prophylactic immunization with HPV-16/18 ASO4-adjuvanted vaccine
title_full_unstemmed Analysis of peripheral blood immune cells after prophylactic immunization with HPV-16/18 ASO4-adjuvanted vaccine
title_sort analysis of peripheral blood immune cells after prophylactic immunization with hpv-16/18 aso4-adjuvanted vaccine
publisher Index Copernicus International S.A.
series Postępy Higieny i Medycyny Doświadczalnej
issn 0032-5449
1732-2693
publishDate 2015-04-01
description Persistent infection with oncogenic types of human papillomavirus (HPV) is a causal factor for more than 99% of cervical cancers. Recently, prophylactic vaccines have been developed to prevent infections with cancer-associated HPV types (HPV16 and HPV18). The aim of this study was to analyze the changes in the immune system that occur within four weeks of the first dose of HPV-16/18 ASO4-adjuvanted vaccine. Assessment of the percentages of selected cell populations in peripheral blood of 20 healthy volunteers vaccinated with Cervarix was performed using flow cytometry. The analysis revealed an increase in the proportion of activated B and CD4+ T helper cells and an absence of significant differences in cytotoxic CD8+ T lymphocytes, indicating activation of the humoral response after vaccination, without a significant effect on cellular response. There were no significant changes in the NK cell population, and there was a reduction of the percentage of NKT-like cells, which may result from expiry of the primary response at the time of analysis. The presented results are preliminary, and in the context of the increasing use of the anti-HPV vaccine, it would be worth continuing the study in larger groups of patients and at earlier and later time points in combination with the measurement of specific anti-HPV16 and -HPV18 antibody levels. Such an assessment could therefore contribute not only to better understanding of the exact mechanism of action of the vaccine, but also to defining the immunological parameters that determine its effectiveness.
topic cervical cancer
human papilloma virus (HPV)
prophylactic vaccine
immune cell response
url http://phmd.pl/gicid/01.3001.0009.6529
work_keys_str_mv AT iwonahus analysisofperipheralbloodimmunecellsafterprophylacticimmunizationwithhpv1618aso4adjuvantedvaccine
AT joannagonetsebastianka analysisofperipheralbloodimmunecellsafterprophylacticimmunizationwithhpv1618aso4adjuvantedvaccine
AT agatasurdacka analysisofperipheralbloodimmunecellsafterprophylacticimmunizationwithhpv1618aso4adjuvantedvaccine
AT agnieszkabojarskajunak analysisofperipheralbloodimmunecellsafterprophylacticimmunizationwithhpv1618aso4adjuvantedvaccine
AT jacekrolinski analysisofperipheralbloodimmunecellsafterprophylacticimmunizationwithhpv1618aso4adjuvantedvaccine
_version_ 1725589746351079424